Literature DB >> 17013821

Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health.

W Kievit1, P M J Welsing, E M M Adang, A M Eijsbouts, P F M Krabbe, P L C M van Riel.   

Abstract

OBJECTIVE: Recently, the use of patient self-reporting instruments instead of clinical, objective measurements to assess rheumatoid arthritis (RA) patients was proposed. This assumes a constant association between disease activity and the self-reporting instruments. The objective was to explore the association (in time) between disease activity and patient perception of general health, disease activity, pain, and functional disability in patients with RA.
METHODS: Data of 624 newly diagnosed RA patients who completed 3 years of followup were analyzed. Cross-sectional linear regression models and longitudinal regression models were estimated, with a visual analog scale (VAS) measuring general health (VAS-GH; 0 = best, 100 = worst) as a dependent variable and the Disease Activity Score (DAS28) without the VAS-GH as an independent variable. Other dependent variables were VAS disease activity, pain, and the Health Assessment Questionnaire.
RESULTS: The DAS28 and VAS-GH were significantly associated in RA patients (P < 0.001). However, the explained variance was low (6.7%). From diagnosis to 3 years after the diagnosis, the intercept decreased given the same regression coefficient. The longitudinal regression model showed that the VAS-GH improved during disease course independent of a change in DAS28. Analyses on the other outcome parameters showed similar results.
CONCLUSION: Patients' perception of health can be different with equal disease activity, depending on the moment in the disease course. Furthermore, our results indicate that self-reported measures on functionality, disease activity, and general health cannot substitute for objective measures of disease activity in RA in longitudinal studies; subsequently, both need to be measured.

Entities:  

Mesh:

Year:  2006        PMID: 17013821     DOI: 10.1002/art.22225

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis.

Authors:  Wietske Kievit; Laura van Hulst; Piet van Riel; Liana Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity.

Authors:  Michael M Ward; Lori C Guthrie; Abhijit Dasgupta
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

3.  Measures of arthritis activity associated with patient-reported improvement in rheumatoid arthritis when assessed prospectively versus retrospectively.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

4.  Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.

Authors:  Yvonne C Lee; Jing Cui; Bing Lu; Michelle L Frits; Christine K Iannaccone; Nancy A Shadick; Michael E Weinblatt; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2011-06-08       Impact factor: 5.156

5.  Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis.

Authors:  Liseth Siemons; Peter M ten Klooster; Harald E Vonkeman; Mart A F J van de Laar; Cees A W Glas
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

6.  Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis.

Authors:  Eva C Scharbatke; Frank Behrens; Marc Schmalzing; Michaela Koehm; Gerd Greger; Holger Gnann; Harald Burkhardt; Hans-Peter Tony
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-10-01       Impact factor: 4.794

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.